69,70 Patients in a phase 2 clinical trial employing curcumin in 21 patients with advanced pancreatic cancer demonstrated clinical indications of tumor regression after receiving 8 g/day of curcumin orally for 8 weeks
We suggest that loss of cuproprotein function is at the core of ALS pathology, a condition that is driven by a combination of unbound copper and ROS that can either initiate and/or accelerate protein aggregation
This may include evidence of weight loss, improved health conditions, and compliance with post-surgical guidelines
This apparent safety in rodents spanning 30+ years of research from multiple independent laboratories is genuine
Ding, C., Shrestha, R., Zhu, X., Geller, A
Current Treatment Options in Gastroenterology, 18 (1), 3342